/SABS
SABS Stock - SAB Biotherapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.99+1.01%
+$0.04 (+1.01%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+75.4%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SABS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.95 – $4.03
TARGET (TP)$7.00
STOP LOSS$3.67
RISK/REWARD1:9.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.59
52W High$6.60
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.32M | $2.24M | $23.90M | $60.88M | $55.24M |
| Gross Profit | $-3,470,185 | $-1,506,000 | $20.61M | $59.22M | $55.24M |
| Gross Margin | -262.4% | -67.3% | 86.2% | 97.3% | 100.0% |
| Operating Income | $-42,910,520 | $-38,075,000 | $-28,918,000 | $-13,393,000 | $20.56M |
| Net Income | $-34,105,309 | $-42,194,000 | $-18,741,000 | $-17,145,000 | $20.12M |
| Net Margin | -2579.0% | -1884.5% | -78.4% | -28.2% | 36.4% |
| EPS | $-3.68 | $-7.64 | $-4.31 | $-3.94 | $4.63 |
Company Overview
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 175.7% Upside
Now
$7
Low
$11
Average
$15
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | Guggenheim | Initiation | Buy | $15 |
| September 17th 2025 | Leerink Partners | Initiation | Outperform | $7 |
| May 14th 2025 | H.C. Wainwright | Resumed | Buy | $10 |
| October 9th 2024 | Craig Hallum | Initiation | Buy | $11 |
| August 28th 2024 | Oppenheimer | Initiation | Outperform | $12 |
Earnings History & Surprises
SABSBeat Rate
41%
Last 17 quarters
Avg Surprise
-272.6%
EPS vs Estimate
Beats / Misses
7/9
1 met exactly
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q2 24
-445.2%
$-3.38vs$-0.62
Q2 24
+44.9%
$-0.54vs$-0.98
Q3 24
+30.1%
$-0.79vs$-1.13
Q4 24
-4.7%
$-1.12vs$-1.07
Q1 25
-6.0%
$-1.23vs$-1.16
Q2 25
+44.0%
$-0.56vs$-1.00
Q3 25
-32.9%
$-1.09vs$-0.82
Q4 25
+64.4%
$-0.21vs$-0.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.59 | $-0.21 | +64.4% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.82 | $-1.09 | -32.9% | ✗ MISS |
Q2 2025 | May 9, 2025 | $-1.00 | $-0.56 | +44.0% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-1.16 | $-1.23 | -6.0% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-1.07 | $-1.12 | -4.7% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-1.13 | $-0.79 | +30.1% | ✓ BEAT |
Q2 2024 | May 20, 2024 | $-0.98 | $-0.54 | +44.9% | ✓ BEAT |
Q2 2024 | Apr 1, 2024 | $-0.62 | $-3.38 | -445.2% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-1.00 | $-1.00 | 0.0% | = MET |
Q3 2023 | Aug 21, 2023 | $-1.60 | $-1.40 | +12.5% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-0.80 | $-1.50 | -87.5% | ✗ MISS |
Q2 2023 | Apr 14, 2023 | $-0.04 | $-1.56 | -3807.0% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $-1.40 | $-1.60 | -14.3% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-1.30 | $-1.10 | +15.4% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-1.20 | $-1.50 | -25.0% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.11 | $-0.66 | -500.0% | ✗ MISS |
Q4 2021 | Nov 22, 2021 | $-0.09 | $-0.02 | +77.8% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | — | $-0.68 | — | — |
Q2 2021 | May 21, 2021 | — | $0.32 | — | — |
Latest News
Guggenheim Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $15
📈 PositiveBenzinga•Dec 19, 2025, 02:04 PM
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
📈 PositiveBenzinga•Dec 18, 2025, 12:36 PM
SAB Biotherapeutics Announces Confirmatory Data From Phase 1 Trial Of SAB-142 In Single- And Multiple-Ascending Dose Among Healthy Volunteers, Including Re-Dosed Cohort, And T1D Patients
📈 PositiveBenzinga•Dec 17, 2025, 01:05 PM
SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia
📈 PositiveBenzinga•Dec 8, 2025, 01:11 PM
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
📈 PositiveBenzinga•Nov 17, 2025, 12:13 PM
SAB Biotherapeutics To Present Phase 1 Data Demonstrating SAB-142's Multi-Specific Mechanism Of Action, Sustained Immunomodulation, Favorable Safety Profile Without Serum Sickness Or Anti-Drug Antibodies, And A Novel Pharmacokinetic Assay For Measuring The Drug
📈 PositiveBenzinga•Nov 4, 2025, 01:37 PM
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
📈 PositiveBenzinga•Sep 19, 2025, 03:59 PM
SAB Biotherapeutics Showcases SAB-142 Data At EASD; Phase 2b SAFEGUARD Study In New-Onset Stage 3 T1D Underway; INNODIA MELD-ATG Results Further Validate Disease-Modifying Potential
📈 PositiveBenzinga•Sep 19, 2025, 11:28 AM
SAB Biotherapeutics shares are trading higher. Leerink Partners initiated coverage on the stock with an Outperform rating and a price target of $7.
📈 PositiveBenzinga•Sep 17, 2025, 06:44 PM
Leerink Partners Initiates Coverage On SAB Biotherapeutics with Outperform Rating, Announces Price Target of $7
📈 PositiveBenzinga•Sep 17, 2025, 12:20 PM
SAB Biotherapeutics To Present At The 61st Annual Meeting Of The European Association For The Study Of Diabetes (Easd) Being Held September 15 – 19, 2025 At The Viecon - Vienna Congress & Convention Center In Vienna, Austria
➖ NeutralBenzinga•Sep 3, 2025, 08:18 PM
Frequently Asked Questions about SABS
What is SABS's current stock price?
SAB Biotherapeutics, Inc. (SABS) is currently trading at $3.99 per share. The stock has moved +1.01% today.
What is the analyst price target for SABS?
The average analyst price target for SABS is $7.00, based on 1 analyst.
What sector is SAB Biotherapeutics, Inc. in?
SAB Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SABS's market cap?
SAB Biotherapeutics, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does SABS pay dividends?
No, SAB Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PLUR
Pluri Inc.
$3.40
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to SABS for comparison